Open Access article distributed under the terms of the Creative Commons License [CC BY-NC-ND 4.0] http://creativecommons.org/licenses/by-nc-nd/4.0

ISSN 2078-6190 EISSN 2078-6204 © 2019 The Author(s)

#### **PRODUCT FOCUS**

# Focus on: Orphenadrine citrate as a muscle relaxant

L Steyn

Amayeza Info Services

The term "skeletal muscle relaxants" represents a broad group of drugs that are structurally and pharmacologically diverse.

Skeletal muscle relaxants are used to treat both spasticity and local musculoskeletal spasms. These two conditions differ in their aetiology, with spasticity originating centrally more as a result of a motor neuron disorder, while local musculoskeletal spasms occur peripherally and more as a result of trauma or muscle strain. For this reason, centrally-acting (e.g. baclofen) and peripherally-acting skeletal muscle relaxants (e.g. orphenadrine, cyclobenzaprine) cannot be used interchangeably. Orphenadrine is used to relieve musculoskeletal spasm originating from painful peripheral musculoskeletal conditions.

#### **Mechanism of action**

Orphenadrine is structurally similar to diphenhydramine, but has less antihistaminic activity.<sup>2,3</sup> It also has a less sedating effect than diphenhydramine, having a slight euphorigenic effect.<sup>4,5</sup> The precise mechanism of action of orphenadrine is not known, but it appears to indirectly relieve muscle pain through central atropine-like effects.<sup>3</sup>It does not work directly on the muscle to relieve muscle spasm and does not affect normal muscle tone.<sup>3,5</sup>

## **Indications**

Oral orphenadrine is indicated for use in conditions involving skeletal muscle spasm, such as lower back pain and torticollis, as well as those conditions resulting from trauma, such as whiplash.<sup>5</sup> The orphenadrine 100 mg tablets are recommended for short-term use.<sup>3</sup>

## **Pharmacokinetics**

Orphenadrine is 95% bioavailable after oral absorption.<sup>2</sup> Time to peak concentration after oral administration is 2 to 4 hours.<sup>2</sup> It is extensively metabolised in the liver through the cytochrome P450 (CYP450) system and the metabolites are primarily eliminated in the urine.<sup>1,3</sup> The elimination half-life (t1/2) of orphenadrine varies between 13.2 to 20.1 hours.<sup>2</sup>

### **Dosing**

One tablet of orphenadrine 100 mg may be taken two or three times daily.<sup>5</sup> The tablets may be taken without regard to meals.<sup>6</sup>

## **Efficacy**

Skeletal muscle relaxants have been found to be more effective than placebo when used for short-term relief of back pain.<sup>3</sup>Peak effects occur after two to four hours and can last for up to 6 hours.<sup>3</sup> Skeletal muscle relaxants may be used in combination another with analgesics for lower back pain. They may also be used as an alternative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients who are not able to tolerate NSAIDs, or who have renal dysfunction.<sup>7</sup>

## Safety of orphenadrine

#### Adverse effects

The side-effect profile of orphenadrine is mainly related to the anticholinergic effects of the drug.<sup>3</sup> These side-effects usually occur at higher doses and may include:

- Dry mouth, nausea, blurring of vision<sup>8</sup>
- Drowsiness<sup>8</sup>
- Increased intraocular pressure<sup>4</sup>
- · Urinary retention4
- CNS stimulation (especially in elderly people)<sup>4</sup>
- Constipation

For this reason, oral orphenadrine is contraindicated for use in patients with<sup>6</sup>:

- Myasthenia gravis
- Gastrointestinal (GI) obstruction
- Glaucoma
- Bladder obstruction or other urinary tract obstruction
- · Prostatic hypertrophy

Oral orphenadrine should also be used with caution in patients with:

- · Heart failure (palpitations, tachycardia)6
- Gastro-oesophageal reflux<sup>6</sup>
- Hepatic disease, renal impairment, or renal disease<sup>6</sup>
- A history of substance abuse, due its euphoric effects (can occur at therapeutic doses)<sup>6</sup>

8 S Afr Fam Pract 2019;61(3):6-8

### Long-term use

Safety and efficacy of long-term use of orphenadrine has not been established.<sup>6</sup> It is recommended that periodic blood, urine, and liver function tests should be performed if orphenadrine is used long term.<sup>4</sup>Chronic use of orphenadrine 100 mg should be tapered slowly before discontinuation.<sup>3</sup>

## Use in the elderly

Careful consideration should be taken in recommending orphenadrine to people over 65 years of age, due to the increased risk of anticholinergic side-effects, drowsiness and the associated increased risk for falls.<sup>3</sup>

## **Drug** interactions

Although metabolised by CYP450, orphenadrine being a minor substrate and weak inhibitor, is less likely to be involved in drug interactions.<sup>3</sup> Increased CNS depression may occur when orphenadrine is taken with other CNS depressants, including alcohol.<sup>1</sup>

#### **Conclusion**

Skeletal muscle relaxants, including orphenadrine are usually recommended for short term use in the treatment of painful musculoskeletal conditions.<sup>3,6</sup> They are recommended for use in conjunction with other non-drug measures, such as rest and physical therapy.<sup>6</sup> If orphenadrine preparations are used

in combination with other analgesics such as paracetamol, contraindications and precautions for each individual ingredient should be taken into account.<sup>4</sup>

#### **References:**

- Fudin J, Raouf M. Practical Pain Management. A Review of Skeletal Muscle Relaxants for Pain Management. Vol 16, Issue 5.[updated 11 April 2017; cited 5 June 2019] Available from: <a href="https://www.practicalpainmanagement.com/treatments/rehabilitation/applying-kinesiology-multi-prong-approach-pain-management">https://www.practicalpainmanagement.com/treatments/rehabilitation/applying-kinesiology-multi-prong-approach-pain-management</a>
- Orphenadrine citrate. In: Medicines Complete. Greenwood Village (CO): Truven Health Analytics; publication year [5 June 2019]. Available from: www. micromedexsolutions.com. Subscription required to view.
- Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, Valaer C. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 2014 Jun;39(6):427-35. PubMed PMID: 25050056; PubMed Central PMCID: PMC4103716. Available from: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103716/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103716/</a>
- AHFS\* Drug Information. Online via Medicines Complete. Orphenadrine citrate.© Copyright, 1959-2019, Selected Revisions January 1, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
- 5. Package Insert. Norflex®. iNova Pharmaceuticals (Pty) Ltd. 21 Feb 1985.
- Prescribers' Digital Reference (PDR). Orphenadrine citrate- Drug Summary. ©2019. Available from: <a href="https://www.pdr.net/drug-summary/Orphenadrine-Citrate-Extended-Release-Tablets-orphenadrine-citrate-1580">https://www.pdr.net/drug-summary/Orphenadrine-Citrate-Extended-Release-Tablets-orphenadrine-citrate-1580</a>
- See S, Ginzburg R. Choosing a Skeletal Muscle Relaxant. American Family Physician. 2008 Aug 1;78(3):365-370. Available from: <a href="https://www.aafp.org/afp/2008/0801/p365.html">https://www.aafp.org/afp/2008/0801/p365.html</a>
- Australian Product Information-Norflex (orphenadrine citrate) tablets. iNova Pharmaceuticals (Australia) Pty Limited. 3 Oct 2018. Available from: <a href="http://www.guildlink.com.au/gc/ws/ia/pi.cfm?product=iapnorfx11018">http://www.guildlink.com.au/gc/ws/ia/pi.cfm?product=iapnorfx11018</a>